| Howsiya Sethukavalan, MD | |
|
309 Jackson St, Monroe, LA 71201-7407 | |
| (318) 966-4541 | |
| (318) 966-4543 |
| Full Name | Howsiya Sethukavalan |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 5 Years |
| Location | 309 Jackson St, Monroe, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295397230 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 331168 (Louisiana) | Primary |
| 207Q00000X | Family Medicine | 125.074069 (Illinois) | Secondary |
| 207Q00000X | Family Medicine | 331168 (Louisiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Glenwood Regional Medical Center | West monroe, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hni Medical Services At Glenwood Llc | 0547518920 | 35 |
| Physician Group Of Louisiana Inc | 8921147067 | 29 |
News Archive
In the UK and US, many websites are selling direct to user self-sampling and testing kits to detect SARS-CoV-2. Recently, a cross-sectional observational study was carried out to check the completeness and accuracy of information provided by these websites.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
› Verified 8 days ago
| Entity Name | Physician Group Of Louisiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316188998 PECOS PAC ID: 8921147067 Enrollment ID: O20091202000287 |
News Archive
In the UK and US, many websites are selling direct to user self-sampling and testing kits to detect SARS-CoV-2. Recently, a cross-sectional observational study was carried out to check the completeness and accuracy of information provided by these websites.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
› Verified 8 days ago
| Entity Name | St Francis Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134405087 PECOS PAC ID: 5092970624 Enrollment ID: O20120706000094 |
News Archive
In the UK and US, many websites are selling direct to user self-sampling and testing kits to detect SARS-CoV-2. Recently, a cross-sectional observational study was carried out to check the completeness and accuracy of information provided by these websites.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
› Verified 8 days ago
| Entity Name | Hni Medical Services At Glenwood Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669962064 PECOS PAC ID: 0547518920 Enrollment ID: O20180801000659 |
News Archive
In the UK and US, many websites are selling direct to user self-sampling and testing kits to detect SARS-CoV-2. Recently, a cross-sectional observational study was carried out to check the completeness and accuracy of information provided by these websites.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Howsiya Sethukavalan, MD 5959 S Sherwood Forest Blvd, Baton Rouge, LA 70816-6038 Ph: (318) 966-4543 | Howsiya Sethukavalan, MD 309 Jackson St, Monroe, LA 71201-7407 Ph: (318) 966-4541 |
News Archive
In the UK and US, many websites are selling direct to user self-sampling and testing kits to detect SARS-CoV-2. Recently, a cross-sectional observational study was carried out to check the completeness and accuracy of information provided by these websites.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases," according to a Global Fund press release.
› Verified 8 days ago
Charles W Mason, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 920 Oliver Rd, Monroe, LA 71201 Phone: 318-807-4730 Fax: 318-812-6450 | |
Dr. Thomas James Gullatt, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 309 Jackson St, Monroe, LA 71201 Phone: 318-966-4541 Fax: 319-966-4543 | |
Jasmine Ledet, NP Hospitalist Medicare: Medicare Enrolled Practice Location: 309 Jackson St, Monroe, LA 71201 Phone: 318-966-4541 Fax: 318-966-4543 | |
Dr. Navin Ramlal, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 309 Jackson St, Monroe, LA 71201 Phone: 318-966-4541 Fax: 318-966-4543 | |
Ayn Morato, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 309 Jackson St, Monroe, LA 71201 Phone: 318-966-4541 Fax: 318-966-4543 | |
Sourabh Bidhan, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4864 Jackson St, Monroe, LA 71202 Phone: 346-351-0795 |